NovoCure (NVCR) Cash from Financing Activities (2014 - 2026)

NovoCure has disclosed Cash from Financing Activities across 13 years of filings, most recently posting -$166000.0 for Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at -$166000.0, down 103.16% year-over-year; the trailing twelve-month figure through Mar 2026 was -$456.8 million (down 579.04% YoY), and the FY2025 annual result was -$451.3 million, down 599.74% from the prior year.
• Cash from Financing Activities came in at -$166000.0 for Q1 2026 at NovoCure, up from -$559.5 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $100.5 million in Q3 2025 to a low of -$559.5 million in Q4 2025.
• The 5-year median for Cash from Financing Activities is $3.1 million (2022), against an average of -$19.4 million.
• Peak annual rise in Cash from Financing Activities reached 100417.0% in 2025, while the deepest fall reached 20937.77% in 2025.
• NovoCure's Cash from Financing Activities stood at $3.4 million in 2022, then slumped by 43.99% to $1.9 million in 2023, then soared by 40.58% to $2.7 million in 2024, then sank by 20937.77% to -$559.5 million in 2025, then soared by 99.97% to -$166000.0 in 2026.
• The last three Cash from Financing Activities figures came in at -$166000.0 (Q1 2026), -$559.5 million (Q4 2025), and $100.5 million (Q3 2025), per Business Quant data.